Teacher Retirement System of Texas Sells 49,372 Shares of Illumina, Inc. $ILMN

Teacher Retirement System of Texas trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 620,358 shares of the life sciences company’s stock after selling 49,372 shares during the quarter. Teacher Retirement System of Texas owned 0.39% of Illumina worth $59,188,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rise Advisors LLC lifted its position in shares of Illumina by 173.6% during the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 224 shares during the last quarter. Cullen Frost Bankers Inc. bought a new stake in shares of Illumina during the second quarter worth $41,000. Golden State Wealth Management LLC raised its holdings in shares of Illumina by 123.2% in the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock valued at $42,000 after acquiring an additional 292 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of Illumina by 2,936.8% in the first quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock valued at $46,000 after acquiring an additional 558 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Illumina by 63.1% in the second quarter. Blue Trust Inc. now owns 654 shares of the life sciences company’s stock valued at $62,000 after acquiring an additional 253 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Weiss Ratings restated a “sell (d+)” rating on shares of Illumina in a report on Saturday. Barclays lifted their price objective on Illumina from $90.00 to $95.00 and gave the company an “underweight” rating in a report on Thursday, October 2nd. Wall Street Zen downgraded Illumina from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Scotiabank downgraded Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price objective for the company. in a report on Friday, July 11th. Finally, Stephens set a $110.00 price objective on Illumina and gave the company an “overweight” rating in a report on Monday, August 4th. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $115.25.

Illumina Price Performance

ILMN opened at $100.11 on Monday. The business’s 50-day moving average is $98.17 and its two-hundred day moving average is $91.76. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The firm has a market capitalization of $15.39 billion, a PE ratio of 12.67, a price-to-earnings-growth ratio of 2.47 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the firm earned $0.36 earnings per share. The company’s revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.